Search

Displaying results 3521 - 3530 of 3592 in total
  1. Drug

    Nifuratel

    go.drugbank.com/drugs/DB13724
    Investigational

    Mixtures: MACMIROR COMPLEX, MACMIROR COMPLEXCategories: Genito Urinary System and Sex Hormones
  2. Drug

    Hachimycin

    go.drugbank.com/drugs/DB13302
    Experimental

    Categories: Genito Urinary System and Sex Hormones
  3. Drug

    AVR-RD-02

    go.drugbank.com/drugs/DB17650
    Investigational

    It consists of autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified _ex vivo_ with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that,

  4. Drug

    FT516

    go.drugbank.com/drugs/DB15732
    Investigational

    FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC).

  5. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    With this difference in potency in mind, other pharmacokinetic considerations such as dose titration, daily dosing, and optimal plasma concentration can be considered the same as for the equivalent amount

  6. Drug

    Sulfaphenazole

    go.drugbank.com/drugs/DB06729
    Approved

    Sulfaphenazole is a sulfonamide antibacterial.

    Categories: Genito Urinary System and Sex Hormones
  7. Drug

    Apomorphine

    go.drugbank.com/drugs/DB00714
    ApprovedInvestigational

    Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an e...

    Categories: Genito Urinary System and Sex Hormones
  8. Drug

    Fulzerasib

    go.drugbank.com/drugs/DB21609
    Investigational

    The usage of the INN stem '-rasib' in the name indicates that Fulzerasib is a Ras protein inhibitor.

  9. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag binds to the transmembrane domain of TPOR expressed on megakaryocytes, and causes the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells [FDA … Higher percentages (65-78%) of the patients receiving lusutrombopag required no platelet transfusion prior to the primary invasive procedure compared to those receiving placebo [L4166].

  10. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    Coagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. … Compared to Coagulation Factor XIII A-Subunit (Recombinant), which is produced through recombinant DNA technology where the target protein is grown in yeast and then isolated, the human form is isolated